Dr Liz Dallimore, Managing Director of Argenica Therapeutics, spoke to MarketOpen about how an AI enabled reanalysis of the Phase 2 trial has clarified ARG 007’s efficacy in patients with severe acute ischaemic stroke.
Nexsen Limited (ASX:NXN) has begun clinical trials for its StrepSure® GBS Rapid Sensor, marking a pivotal step toward transforming real-time maternal diagnostics.
Argenica Therapeutics may have cracked the code on treating brain injury, with a ferret study showing its lead drug ARG-007 delivers lasting protection where no approved therapy exists.
Argenica Therapeutics has secured a new US patent that positions its lead drug, ARG-007, at the forefront of preventing stroke not just in emergency rooms, but in operating theatres
With all 92 stroke patients now treated, Argenica’s Phase 2 trial of ARG-007 heads into the critical data lock phase — and the biotech world is watching closely.
In a world-first clinical trial, Tryp Therapeutics is testing whether a psychedelic infusion can curb the compulsions of the most common eating disorder in the US.
Orthocell’s FDA clearance for its Remplir™ nerve repair device marks a major commercial milestone, unlocking access to the US$1.6 billion US market and positioning the Perth-based company for global growth and profitability.
Argenica Therapeutics’ ARG-007 has demonstrated compelling neuroprotective effects in preclinical models of traumatic brain injury, reducing brain cell damage and neuroinflammation to levels comparable with non-injured subjects.
Argenica Therapeutics (ASX:AGN) moves closer to a potential breakthrough in stroke treatment as its Phase 2 trial of ARG-007 nears completion with a final safety endorsement from the DSMB.
Island Pharmaceuticals groundbreaking PROTECT trial advances with full enrolment in Phase 2b, aiming to combat dengue fever through the repurposed antiviral ISLA-101.